• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>GlaxoSmithKline

GlaxoSmithKline

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. EU Approves GlaxoSmithKline and Genmab's Leukemia Treatment

    EU Approves GlaxoSmithKline and Genmab's Leukemia Treatment

  2. Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program

    Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program

  3. China charges foreign investigators linked to Glaxo case

    China charges foreign investigators linked to Glaxo case

  4. EU Approves Glaxo's Mekinist as Melanoma Treatment

    EU Approves Glaxo's Mekinist as Melanoma Treatment

  5. Research and Markets: Global Age-Related Macular Degeneration (AMD) Market 2014-2018

    Research and Markets: Global Age-Related Macular Degeneration (AMD) Market 2014-2018

  6. Research and Markets: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US Drug Forecast and Market Analysis to 2022

    Research and Markets: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - US Drug Forecast and Market Analysis to 2022

  7. Research and Markets: Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

    Research and Markets: Cervarix (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

  8. Research and Markets: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022

    Research and Markets: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - Canada Drug Forecast and Market Analysis to 2022

  9. Research and Markets: Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

    Research and Markets: Gardasil (Prophylactic Human PapillomaVirus Vaccines) - Forecast and Market Analysis to 2022

  10. Research and Markets: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

    Research and Markets: PharmaPoint: Prophylactic Human Papillomavirus Vaccines - 5EU Drug Forecast and Market Analysis to 2022

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.